Product Information

DALIRESP 250 MCG TABLET is a brand product labeled by AstraZeneca Pharmaceuticals LP, priced at $14.9826 per EA under NDC 00310008839. Its NADAC has been published 405 times since Nov 21, 2018.

FDA first approved this application on Feb 28, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the roflumilast market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for DALIRESP 250 MCG TABLET has been published 405 times since Nov 21, 2018, and over the history we have for it it has risen 33.6%. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.